Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Accord Healthcare Adds Generic Drug Approved for the Treatment of Relapsing MS
Accord Healthcare, a leading generic pharmaceutical company, has added Teriflunomide to its portfolio of oral […]
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer has announced the US Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the […]
AnnJi Pharmaceutical Announced a Licensing Agreement With Avenue Therapeutics For The Treatment Of Kennedy's Disease
AnnJi Pharmaceutical has entered into an exclusive license agreement with Avenue Therapeutics for the development and […]
AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B
AusperBio has announced the completion of the first cohort dosing in a Phase 1 clinical […]
FDA Accepts Supplemental New Drug Application for Jardiance® for Children 10 years and Older with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for […]
Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort
Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs […]
Personalis Selected for Clinical Research by AstraZeneca After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Personalis, a leader in advanced genomics for precision oncology, today announced it will continue its […]
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) accepted for Priority […]
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Pharmapack 2023 a Pivotal Moment for Sustainability in Drug Delivery and Packaging
Pharmapack Europe 2023 (February 1-2, 2023) closed earlier this month with the drug delivery and packaging […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more